Shanhe Pharmaceutical Excipients released its 2026 interim report on August 22, 2026. The company's total operating revenue was 522 million yuan, net profit attributable to the parent company was 96.1892 million yuan, and net cash inflow from operating activities was 91.0085 million yuan. The company's latest asset-liability ratio was 38.34 percent, up 2.19 percentage points from the previous quarter and up 0.64 percentage points from the same period last year. The latest gross margin was 32.06 percent, down 0.23 percentage points from the previous quarter and down 0.26 percentage points from the same period last year. The latest return on equity was 9.30 percent, down 0.78 percentage points from the same period last year. Diluted earnings per share were 0.41 yuan, and the latest inventory turnover ratio was 3.53 times, down 0.06 times from the same period last year. The company had 16,000 shareholders, and the top ten shareholders held 93.3768 million shares, accounting for 39.83 percent of total share capital.
Anhui Sunhere Pharmaceutical Excipients Co LtdInterim report shows net profit and revenue, but no comparative expectations or market reaction; mixed indicators.
